Eltrombopag + Telitacicept vs Eltrombopag in Steroid-Refractory/Relapsed ITP

Phase 2, randomised, open-label trial of telitacicept in immune thrombocytopenia (ITP) (2 arms), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Proportion of patients maintaining platelet count ≥30×10⁹/L with no bleeding at 24 weeks. Planned start Jul 2026; status: not yet recruiting.